Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025
Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed”) is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading. The Nasdaq‑listed psychedelic biotech disclosed that it has secured a sustainable, pharmaceutical‑grade ibogaine supply through its strategic partner PsyLabs, including an initial shipment of 50 kg of high‑potency iboga bark that is now being processed into ibogaine HCl and full‑spectrum Total Alkaloid Extracts for global clinical and therapeutic markets. GlobeNewswire+1 At the same time, Psyence BioMed’s stock was flagged by Benzinga among Thursday’s top